Clinical trials: Eyes With Retinal Diseases
Age - Related Macular Degeneration (AMD)
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment.
- Trial name
- PERSPECTIVE (NCT07164378)
- Testing
- Lens-Exchange, Add-on
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- VisionCare, Inc.
Stargardt Disease, Cone Rod Dystrophy
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and…
- Conditions
- Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
- Trial name
- NCT06467344
- Testing
- ACDN-01
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ascidian Therapeutics, Inc
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with…
- Trial name
- GALLEGO (NCT03972709)
- Testing
- Galegenimab
- Where
- 72 sites in United States
- Volunteers
- 372 people
- Sponsor
- Genentech, Inc.
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Retinitis Pigmentosa, Retinal Degeneration
NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases
The study objective is to demonstrate safety of the NR 600 System, and to evaluate the performance of the device in restoring visual activity of daily living in subjects with retinal degenerative diseases and severe visual…
- Trial name
- NR (NCT04295304)
- Testing
- Retinal surgery with implantation of epi-retinal device
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Nano Retina
Retinitis Pigmentosa
Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.
- Trial name
- NCT03073733
- Testing
- human retinal progenitor cells, Mock injection
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- jCyte, Inc
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Age-Related Macular Degeneration
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
This is an open-label, Phase 1 single-center study in approximately 40 subjects who have 1 eye with intermediate AMD, including a high-risk drusen without geographic atrophy (GA) subgroup and a noncentral GA subgroup.
- Trial name
- NCT02848313
- Testing
- Elamipretide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stealth BioTherapeutics Inc.
Geographic Atrophy, Age-Related Macular Degeneration
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study…
- Trial name
- NCT05536297
- Testing
- avacincaptad pegol
- Where
- 117 sites in United States, Argentina and 15 more
- Volunteers
- 278 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence…
- Trial name
- PHP (NCT00692887)
- Testing
- PHP - Preferential Hyperacuity Perimeter (Foresee)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic…
- Trial name
- NCT04607148
- Testing
- Galegenimab
- Where
- 48 sites in United States
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
Macular Degeneration
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2.
- Trial name
- NCT02228304
- Testing
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Where
- 38 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Neurotech Pharmaceuticals
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects…
- Trial name
- NCT01940887
- Testing
- E10030, bevacizumab or aflibercept
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 645 people
- Sponsor
- Ophthotech Corporation
Diabetic Macular Edema
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis®…
- Trial name
- OXEYE (NCT05697809)
- Testing
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 3 people
- Sponsor
- Oxular Limited
Macular Edema
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.
- Trial name
- DRAKO (NCT02850263)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Bayer
Bardet-Biedl Syndrome 1, Retinal Degeneration
First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration
The goal of this first in human study is to evaluate the preliminary safety and tolerability of AXV-101 in participants with BBS1.
- Trial name
- AXIS (NCT07269665)
- Testing
- AXV-101
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Axovia Therapeutics
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals